It has been suggested that women with breast cancer and a history of oral contraceptive (OC) use survive significantly longer than breast cancer patients who have not used OCs (Matthews et al., 1981; Spencer et al., 1978) . However Rosner & Lane (1986) and Vessey et al. (1979) (Peto et al., 1977) , and the relative risk of death was determined using Cox regression methods (Cox & Oakes, 1984) .
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A definitive history of use or non-use of OCs had been recorded for 296 patients. Of these, 14 patients were recorded as having bilateral primaries (5.5% (6/109) of OC users and 4.3% (8/187) of non-users), 14 had metastatic disease on admission (5.5% of OC users and 4.3% of nonusers) and 5 had intra-duct carcinomas; these patients were excluded from the main analyses leaving a total of 263 cases. Ninety-four patients (36%) had used OCs for more than 6 months.
The OC users were younger at diagnosis than the nonusers (40.5 years compared to 43.7 years, see Table I ). This is reflected in the higher proportion of premenopausal women in the OC-user group (86%) compared to the nonuser group (75%). The two groups were similar with respect to the major risk factors for breast cancer (age at menarche, age at first full-term pregnancy, and family history of breast cancer) and the major prognostic factors at presentation (clinical T and N stage and oestrogen receptor status, see Table I ). No (Rosner & Lane, 1986; Matthews et al., 1981; Vessey et al., 1979; Spencer et al., 1978) . In two of these studies (Rosner & Lane, 1986; Vessey et al., 1979) , however, this beneficial effect was explained by earlier stage at diagnosis and disappeared when stage of disease at presentation was allowed for in the analysis. Matthews et al. (1981) Matthews et al. (1981) suggested that 'familial' tumours might be less aggressive and hence the survival advantage. All four of these studies (Rosner & Lane, 1986; Matthews et al., 1981; Vessey et al., 1979; Spencer et al., 1978) find evidence that women with breast cancer who have used OCs present with earlier stage disease than non-users but the Royal College of General Practitioners (1981) found the opposite. Vessey et al. (1979) examined the question of surveillance bias (OC users being more likely to have frequent breast examination by a doctor than non-users) in detail. They found that although OC users did have more frequent breast examination than non-users, 85% of tumours in both the user and non-user groups were found by the woman herself or her husband. They concluded that the earlier TNM stage was unlikely to be due to surveillance bias but could be due to a beneficial effect of OCs on tumour growth or spread. In our data, stage at presentation and survival are independent of OC use. Moreover we found the proportion of OC users and non-users with a family history of breast cancer to be similar.
In common with other case series (Rosner & Lane, 1986; Matthews et al., 1981; Spencer et al., 1978) , our study suffers from the drawback that information on OC use is lacking in detail compared to information from a case-control study such as that of Vessey et al. (1979) or a cohort study such as that of the Royal College of General Practitioners (1981) . The OC user group selected by Spencer et al. (1978) was homogeneous in that all these women had used OCs at the time of diagnosis or in the year before, but in all the studies the range of months of use was wide. Our dichotomy at 6 months of use was pre-determined by the form in which the data were collected but seems no more unreasonable than supposing that only a month or two of use could possibly affect survival. Thus our data based on 263 unselected cases lend no support to the idea that oral contraceptives exert a beneficial influence on growth or spread or breast tumours.
